Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström SyndromesGlobeNewsWire • 09/20/21
Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl SyndromeGlobeNewsWire • 09/08/21
Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewsWire • 09/02/21
Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of ObesityGlobeNewsWire • 08/03/21
Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl SyndromeGlobeNewsWire • 07/28/21
Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021GlobeNewsWire • 07/27/21
Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic MutationsBenzinga • 07/23/21
Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyGlobeNewsWire • 07/23/21
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR DeficiencyGlobeNewsWire • 05/21/21
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass EstimatesZacks Investment Research • 05/03/21
Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/21
Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021GlobeNewsWire • 03/20/21
Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021GlobeNewsWire • 03/09/21
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/01/21
Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/10/21
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström SyndromesGlobeNewsWire • 12/22/20